Morrison & Foerster advised ARCH Venture Partners and certain other investors in connection with a Series B financing round it co-led with Cormorant Asset Management totaling $200 million in Erasca, a company on a mission to erase cancer.
Founded in 2018 and headquartered in San Diego, Erasca is advancing multiple programs that shut down key cancer pathways in order to solve oncology’s hardest problems. The company will use the proceeds from the Series B financing round to support the clinical development of multiple promising oncology programs and further advance its in-house drug discovery pipeline.
The MoFo deal team was led by Boston-based corporate partner Ori Solomon, co-chair of the firm’s Emerging Companies + Venture Capital Group, and included ECVC associates Dan Murray and Mike Maroni; technology transactions partner Matt Karlyn and associate Tiffany Quach; and patents partner Janet Xiao and scientific analyst Yujia Sun.
Read the press release.